Amyotrophic lateral sclerosis: Early predictors of prolonged survival

Journal of Neurology

Volumn 253, Issue 11, 2006, Pages 1428-1436

  Czaplinski, Adam ^a   Yen, Albert A ^b   Appel, Stanley H ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

ALS; Outcome predictors; Survival

Indexed keywords

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DELAYED DIAGNOSIS; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; FORCED EXPIRATORY VOLUME; HAZARD ASSESSMENT; HUMAN; KAPLAN MEIER METHOD; LIFE TABLE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; TRACHEOSTOMY; UNIVARIATE ANALYSIS;

ADULT; AGE FACTORS; AGE OF ONSET; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; VITAL CAPACITY;

EID: 33750396937     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-006-0226-8     Document Type: Article

References (36)

1. Appel V, Stewart SS, Smith G, Appel SH (1987) A rating scale for amyotrophic lateral sclerosis: Description and preliminary experience. Ann Neurol 22:328-333
2. Armon C, Graves MC, Moses D, Forte DK, Sepulveda L, Darby SM, Smith RA (2000) Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle Nerve 23:874-882
3. Bensimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330:585-591
4. Brinkmann JR, Andres P, Mendoza M, Sanjak M (1997) Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials. J Neurol Sci 147:97-111
5. Brooks BR (1994) El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 124:96-107
6. Caroscio JT, Mulvihill MN, Sterling R, Abrams B (1987) Amyotrophic lateral sclerosis: its natural history. Neurol Clin 5:1-8
7. Cedarbaum JM, Stambler N (2001) Disease status and use of ventilatory support by ALS patients BDNF Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2:19-22
8. Chancellor AM, Slattery JM, Fraser H, Swingler RJ, Holloway SM, Warlow CP (1993) The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register. J Neurol 240:339-346
9. Chio A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, Bottacchi E, Mutani R (2002) Piemonte and Valle d'Aosta Register for ALS (PARALS) Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 59:99-103
10. Christensen PB, Hojer-Pedersen E, Jensen NB (1990) Survival of patients with amyotrophic lateral sclerosis. Neurology 40:600-604
11. Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187-220
12. Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, Jacobs M, Rothstein JD, Appel SH, Pascuzzi RM, Heiman-Patterson TD, Donofrio PD, David WS, Russell JA, Tandan R, Pioro EP, Felice KJ, Rosenfeld J, Mandler RN, Sachs GM, Bradley WG, Raynor EM, Baquis GD, Belsh JM, Novella S, Goldstein J, Hulihan J (2003) Northeast ALS Consortium A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 61:456-464
13. del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G (2003) Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 60:813-819
14. Eisen A, Schulzer M, MacNeil M, Pant B, Mak E (1993) Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve 116:27-32
15. Haverkamp LJ, Appel V, Appel SH (1995) Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 118:707-719
16. Jablecki C, Berry C, Leach J (1989) Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve 12:833-841
17. Juergens SM, Kurland LT, Okazaki H, Mulder DW (1980) ALS in Rochester, Minnesota, 1925-1977. Neurology 30:463-470
18. Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N, Cedarbaum JM (1999) A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials. J Neurol Sci 169:118-125
19. Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, Rowland LP, Levin B, Mitsumoto H (2005) The ALSFRSr predicts survival time in an ALS clinic population. Neurology 64:38-43
20. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347:1425-1431
21. Lange DJ, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, Lai EC, Murphy MF, Natter HM, Norris FH, Rudnicki S (1996) Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS/IGF-I Study Group. Neurology 47(Suppl 2):S93-94
22. Lange DJ, Murphy PL, Diamond B, Appel V, Lai EC, Younger DS, Appel SH (1998) Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 55:93-96
23. Lee JR, Annegers JF, Appel SH (1995) Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 132:207-215
24. Louwerse ES, Visser CE, Bossuyt PM, Weverling GJ (1997) Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS Consortium. J Neurol Sci 152(Suppl 1):S10-17
25. Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV (2002) Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 25:709-714
26. Mitsumoto H, Davidson M, Moore D, Gad N, Brandis M, Ringel S, Rosenfeld J, Shefner JM, Strong MJ, Sufit R, Anderson FA (2003) ALS CARE Study Group Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler Other Motor Neuron Disord 4:177-185
27. Moore DH, Miller RG (2003) WALS Study Group ALS CARE Study Group ALSRFS as a measure of disease progression and survival. Amyotroph Lateral Scler Other Motor Neuron Disord 4(Suppl 1):C51
28. Norris F, Shepherd R, Denys E, U K, Mukai E, Elias L, Holden D, Norris H (1993) Onset, natural history and outcome in idiopathic motor neuron disease. J Neurol Sci 118:48-55
29. Preux PM, Couratier P, Boutros-Toni F, Salle JY, Tabaraud F, Bernet-Bernady P, Vallat JM, Dumas M (1996) Survival prediction in sporadic amyotrophic lateral sclerosis : age and clinical form at onset are independent risk factors. Neuroepidemiology 15:153-160
30. Ringel SP, Murphy JR, Alderson MK, Bryan W, England JD, Miller RG, Petajan JH, Smith SA, Roelofs RI, Ziter F (1993) The natural history of amyotrophic lateral sclerosis. Neurology 43:1316-1322
31. Stambler N, Charatan M, Cedarbaum JM (1998) Prognostic indicators of survival in ALS. Neurology 50:66-72
32. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM (2000) Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch Neurol 57:1171-1176
33. Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME; NEALS Consortium (2004) Functional outcome measures as clinical trial endpoints in ALS. Neurology 63:1933-1935
34. Turner MR, Parton MJ, Shaw CE, Leigh PN, Al-Chalabi A (2003) Prolonged survival in motor neuron disease a descriptive study of the King's database 1990-2002. J Neurol Neurosurg Psychiatry 74:995-997
35. Tysens OB, Vollset SE, Aarli JA (1991) Epidemiology of amyotrophic lateral sclerosis in Hordaland county, western Norway. Acta Neurol Scand 83:280-285
36. Yen AA, Simpson E, Haverkamp LJ, Appel SH (2004) AALS. ALS and Other Motor Neuron Disorders 5(Suppl1):S1-S5